IL254535A0 - A3 adenosine receptor ligand for managing cytokine release syndrome - Google Patents

A3 adenosine receptor ligand for managing cytokine release syndrome

Info

Publication number
IL254535A0
IL254535A0 IL254535A IL25453517A IL254535A0 IL 254535 A0 IL254535 A0 IL 254535A0 IL 254535 A IL254535 A IL 254535A IL 25453517 A IL25453517 A IL 25453517A IL 254535 A0 IL254535 A0 IL 254535A0
Authority
IL
Israel
Prior art keywords
receptor ligand
adenosine receptor
cytokine release
release syndrome
managing
Prior art date
Application number
IL254535A
Other languages
Hebrew (he)
Original Assignee
Can Fite Biopharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Can Fite Biopharma Ltd filed Critical Can Fite Biopharma Ltd
Priority to IL254535A priority Critical patent/IL254535A0/en
Publication of IL254535A0 publication Critical patent/IL254535A0/en
Priority to CN201880074313.8A priority patent/CN111447953A/en
Priority to US16/647,282 priority patent/US20210069227A1/en
Priority to EP18786053.1A priority patent/EP3681538A1/en
Priority to PCT/IL2018/051034 priority patent/WO2019053723A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
IL254535A 2017-09-17 2017-09-17 A3 adenosine receptor ligand for managing cytokine release syndrome IL254535A0 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
IL254535A IL254535A0 (en) 2017-09-17 2017-09-17 A3 adenosine receptor ligand for managing cytokine release syndrome
CN201880074313.8A CN111447953A (en) 2017-09-17 2018-09-16 A3 adenosine receptor ligands for the management of cytokine release syndrome
US16/647,282 US20210069227A1 (en) 2017-09-17 2018-09-16 A3 adenosine receptor ligand for managing cytokine release syndrome
EP18786053.1A EP3681538A1 (en) 2017-09-17 2018-09-16 A3 adenosine receptor ligand for managing cytokine release syndrome
PCT/IL2018/051034 WO2019053723A1 (en) 2017-09-17 2018-09-16 A3 adenosine receptor ligand for managing cytokine release syndrome

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IL254535A IL254535A0 (en) 2017-09-17 2017-09-17 A3 adenosine receptor ligand for managing cytokine release syndrome

Publications (1)

Publication Number Publication Date
IL254535A0 true IL254535A0 (en) 2017-11-30

Family

ID=61837940

Family Applications (1)

Application Number Title Priority Date Filing Date
IL254535A IL254535A0 (en) 2017-09-17 2017-09-17 A3 adenosine receptor ligand for managing cytokine release syndrome

Country Status (5)

Country Link
US (1) US20210069227A1 (en)
EP (1) EP3681538A1 (en)
CN (1) CN111447953A (en)
IL (1) IL254535A0 (en)
WO (1) WO2019053723A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20240018000A (en) 2022-08-01 2024-02-13 주식회사 넥스트젠바이오사이언스 Novel purine derivative compounds as A3 adenosine receptor agonists

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5443836A (en) 1993-03-15 1995-08-22 Gensia, Inc. Methods for protecting tissues and organs from ischemic damage
US5688774A (en) 1993-07-13 1997-11-18 The United States Of America As Represented By The Department Of Health And Human Services A3 adenosine receptor agonists
EP0708781B1 (en) 1993-07-13 2001-10-04 THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, Department of Health and Human Services A 3 adenosine receptor agonists
JP3125083B2 (en) * 1994-03-18 2001-01-15 株式会社大塚製薬工場 TNF overproduction inhibitor
WO1997027173A2 (en) 1996-01-24 1997-07-31 Sumitomo Chemical Company, Limited Dihalopropene compounds, their use as insecticides/acaricides and intermediates for their production
US6048865A (en) 1997-07-29 2000-04-11 Medco Research, Inc. N6 -substituted-adenosine-5'-uronamides as adenosine receptor modulator
CA2296485A1 (en) 1997-07-29 1999-02-11 Medco Research, Inc. N6-substituted-adenosine-5'-uronamides as adenosine receptor modulators
WO1999020284A1 (en) 1997-10-23 1999-04-29 Trustees Of The University Of Pennsylvania Methods for reducing ischemic injury of the heart via the sequential administration of monophosphoryl lipid a and adenosine receptor agents
IL133680A0 (en) * 1999-09-10 2001-04-30 Can Fite Technologies Ltd Pharmaceutical compositions comprising an adenosine receptor agonist or antagonist
CN101061385B (en) * 2004-12-02 2013-03-20 坎-菲特生物药物有限公司 A biological marker for inflammation
DK1959939T3 (en) * 2005-11-30 2012-04-23 Can Fite Biopharma Ltd APPLICATION OF A3-ADENOSIN RECEPTOR AGONIST IN THE TREATMENT OF Osteoarthritis
CN101410114B (en) 2006-01-26 2012-07-04 美国政府卫生与公共服务部 A3 adenosine receptor allosteric modulators
JP5306238B2 (en) * 2007-03-07 2013-10-02 エフエム・セラピューティクス・カンパニー・リミテッド Adenosine derivative, synthesis method thereof, and pharmaceutical composition for prevention and treatment of inflammatory disease containing the same as an active ingredient
IL284985B2 (en) * 2015-02-18 2023-03-01 Enlivex Therapeutics R& D Ltd Combination immune therapy and cytokine control therapy for cancer treatment
IL242723B (en) * 2015-11-23 2019-12-31 Can Fite Biopharma Ltd An a3 adenosine receptor ligand for use in treating ectopic fat accumulation

Also Published As

Publication number Publication date
US20210069227A1 (en) 2021-03-11
WO2019053723A1 (en) 2019-03-21
CN111447953A (en) 2020-07-24
EP3681538A1 (en) 2020-07-22

Similar Documents

Publication Publication Date Title
HK1252161A1 (en) Chimeric cytokine receptor
ZA201802371B (en) Glucagon receptor agonists
HK1253012A1 (en) Antagonistic anti-tumor necrosis factor receptor superfamily antibodies
HK1252009A1 (en) Antibodies directed against interleukin 36 receptor (il-36r)
HK1253366A1 (en) Triazole agonists of the apj receptor
HK1255163A1 (en) Heteroarylhydroxypyrimidinones as agonists of the apj receptor
HK1253695A1 (en) T-cell receptor specific antibodies
GB201518816D0 (en) Receptor
EP3628005A4 (en) Corticotropin releasing factor receptor antagonists
EP3630763A4 (en) Corticotropin releasing factor receptor antagonists
EP3160479A4 (en) Antagonists for interleukin-17 receptor b (il-17rb) and its ligand il-17b for cancer therapy
GB201702617D0 (en) Receptor
IL292601A (en) Npy2 receptor agonists
SG11202104078PA (en) 5-azaindazole derivatives as adenosine receptor antagonists
IL254535A0 (en) A3 adenosine receptor ligand for managing cytokine release syndrome
ZA201903502B (en) Riser support system
PT3581572T (en) Adenosine a3 receptor modulators
GB201903900D0 (en) Adenosine receptor agonists
GB201619637D0 (en) C3a receptor agonists
GB201817943D0 (en) Galanin-2 receptor agonists
GB2583484B (en) Quick release support
EP3617893C0 (en) Device for managing utilized service
GB201701887D0 (en) Receptor
GB201700926D0 (en) Receptor
TWM533941U (en) Easy-to-clean foot mat for car